Detection of Lung Cancer by Plasma Lipids

Early-Stage Lung Cancer Clinical Trial

— ELAID  

Official title:

Detection of Early-stage Lung Cancer Using Machine Learning and Plasma Metabolomics

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04287712
• Other study ID #: 2018PHB233-01
• Status: Completed
• Start date: December 13, 2018
• Est. completion date: May 20, 2020

Study information

• Verified date: June 2020
• Source: Peking University People's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

There are no reliable blood-based tests currently available for early-stage lung cancer diagnosis. We try to establish a highly accurate method for detecting early-stage lung cancer by combining machine learning with untargeted and targeted metabolomics .

Description:

All plasma lipids were first detected by untargeted metabolomics methods and 9 feature lipids of early-stage lung cancer were selected by support vector machine algorithm. Then, a targeted metabolomics method was developed to detect the 9 lipids quantitatively based on multiple reaction monitoring mode. Finally, a detection model was established based on the 9 lipids.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 558
• Est. completion date: May 20, 2020
• Est. primary completion date: October 31, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. pulmonary nodules or opacity

2. plan to receive surgery

Exclusion Criteria:

1. history of other malignancies

2. received anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery

Related Conditions & MeSH terms

• Early-Stage Lung Cancer
• Lung Neoplasms

Intervention

Diagnostic Test:
• Plasma lipids
Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.

Locations

Country	Name	City	State
China	Peking University People's Hospital	Beijing	Beijing

Sponsors (4)

Lead Sponsor	Collaborator
Peking University People's Hospital	Beijing Haidian Hospital, Jiangsu Cancer Institute & Hospital, Peking University Health Science Center

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma Lipids	A detection model based on 9 lipids were developed, including 3 lysophosphatidylcholines, 5 phosphatidylcholines, and a triglyceride. The 9 lipids were detected by targeted metabolomics by mass spectrometry.	All samples were detected together after participants recruitment and sample collection. All samples were detected within 18 months from sample collection.